Compare CING & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CING | BNGO |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 24.3M |
| IPO Year | 2021 | 2018 |
| Metric | CING | BNGO |
|---|---|---|
| Price | $3.92 | $1.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $31.33 | $6.33 |
| AVG Volume (30 Days) | 130.3K | ★ 291.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $28,720,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.20 | $1.45 |
| 52 Week High | $6.01 | $22.80 |
| Indicator | CING | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 55.60 | 45.27 |
| Support Level | $3.80 | $1.59 |
| Resistance Level | $4.02 | $1.77 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 82.35 | 47.67 |
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.